The purpose of this study is to demonstrate that the rosiglitazone/glimepiride fixed-dose
combination tablet will safely and effectively control glycemia as first-line oral therapy in
drug naïve subjects with type 2 diabetes. This 24-week study will compare the effects of
treatment with rosiglitazone/glimepiride to treatment with glimepiride alone. The primary
objective is to demonstrate superiority of rosiglitazone/glimepiride to glimepiride in
lowering Glycosylated Hemoglobin (HbA1c).